Merus to Present at the 2016 Wedbush PacGrow Healthcare Conference
A live webcast of the presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in
N.V. Shelley Margetson– email@example.com +31 (0)30 253 8800 Argot Partners Kimberly Minarovich– firstname.lastname@example.org 1-212-600-1902